Concord Biotech announces the successful completion of the NAFDAC (National Agency for Food and Drug Administration) inspection at its Oral Solid Dosage (OSD) Unit-2 facility in Valthera, Gujarat. The inspection, conducted from October 06, 2025 to October 07, 2025, underscores Concord Biotech’s commitment to quality, safety, and regulatory compliance. This achievement reflects the company’s dedication to maintaining the highest standards.
NAFDAC Inspection Successfully Concluded
Concord Biotech is pleased to announce the successful completion of the NAFDAC inspection (National Agency for Food and Drug Administration) at their Oral Solid Dosage (OSD) Unit-2 facility located in Valthera, Gujarat. This positive outcome highlights the company’s adherence to international regulatory standards.
Inspection Details and Significance
The NAFDAC inspection was conducted over a two-day period, from October 06, 2025 to October 07, 2025. The successful completion of this inspection underscores Concord Biotech’s unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance in all its operations.
Commitment to Quality and Compliance
This achievement reflects Concord Biotech’s dedication to excellence and its continued focus on meeting the rigorous requirements of global regulatory authorities. The company remains committed to providing high-quality pharmaceutical products while adhering to the strictest regulatory guidelines.
Source: BSE
